Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04660396 · ClinicalTrials.gov registry record
Monitoring Outpatient Blood VolumE in Heart Failure
A clinical trial, sponsored by Daxor Corporation.
- Completed
- Registry status
- 15
- Enrollment target
NCT04660396 is a clinical trial that has completed, run by Daxor Corporation. The registered enrollment target is 15 participants.
The verdict
NCT04660396 has completed, sponsored by Daxor Corporation.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
In patients discharged following heart failure treatment, the consistency of blood volume status and components over time is unknown. The primary objective is to describe the rate of change, if any, of the plasma volume and red blood cell volume following hospitalization and discharge of patients with heart failure.
Interventions
- DEVICE BVA-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2022-07-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04660396
The ClinicalTrials.gov registry entry for NCT04660396 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daxor Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BVA-100 is the first listed.
NCT04660396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04660396 about?
NCT04660396 is a clinical study titled "Monitoring Outpatient Blood VolumE in Heart Failure". In patients discharged following heart failure treatment, the consistency of blood volume status and components over time is unknown. The primary objective is to describe the rate of change, if any, of the plasma volume and red blood cell volume following hospitalization and discharge of patients wi...
What is the current status of trial NCT04660396?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2021-09-16. Estimated completion is 2022-07-30.
What interventions are being tested in trial NCT04660396?
The interventions under investigation include: BVA-100 (DEVICE).
Who is sponsoring clinical trial NCT04660396?
This trial is sponsored by Daxor Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.